What We're Reading: Page 318
Industry reads hand-picked by our editors
Jul 28, 2016
Jul 27, 2016
-
The Street
Why Gilead Can't Easily Copy Celgene's 'Partner Partner Partner' Deal-Making Playbook
-
EP Vantage
Revlimid blow highlights big cap exposure
-
Regulatory Focus
FDA Lowers ANDA Fee Rates for 2017
-
FierceBiotech
Merck shocks ALK by returning rights to allergy immunotherapies
Jul 26, 2016
-
Stat
An ex-con is taking his debt-ridden, cash-burning biotech public. Why are people investing?
-
Endpoints
Building a bulletproof CAR? Scientists engineer a built-in PD-1 shield
-
PMLive
Boehringer stops Gilotrif head and neck cancer trials
-
The Economic Times
US, Venezuela sink Dr Reddy's; five key takeaways
Previous
